M&T Bank
TEVA icon

M&T Bank’s Teva Pharmaceuticals TEVA Stock Holding History

M&T Bank’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.61M Buy
106,646
+8,183
+8% +$273K 0.01% 485
2026
Q1 		$2.97M Buy
+98,463
New +$3.17M 0.01% 500
2019
Q4 		– Sell
-30,303
Closed -$208K – 1621
2019
Q3 		$208K Sell
30,303
-1,656
-5% -$12.7K ﹤0.01% 1405
2019
Q2 		$295K Sell
31,959
-10,775
-25% -$130K ﹤0.01% 1242
2019
Q1 		$669K Buy
42,734
+7,429
+21% +$131K ﹤0.01% 850
2018
Q4 		$545K Sell
35,305
-2,990
-8% -$61.3K ﹤0.01% 878
2018
Q3 		$824K Sell
38,295
-1,356
-3% -$31.5K ﹤0.01% 823
2018
Q2 		$964K Buy
39,651
+918
+2% +$18.7K 0.01% 773
2018
Q1 		$662K Sell
38,733
-63
-0.2% -$1.23K ﹤0.01% 904
2017
Q4 		$734K Sell
38,796
-38,907
-50% -$585K ﹤0.01% 874
2017
Q3 		$1.37M Sell
77,703
-18,523
-19% -$417K 0.01% 657
2017
Q2 		$3.2M Sell
96,226
-11,457
-11% -$355K 0.02% 429
2017
Q1 		$3.46M Sell
107,683
-12,323
-10% -$421K 0.02% 403
2016
Q4 		$4.35M Sell
120,006
-44,141
-27% -$1.76M 0.03% 347
2016
Q3 		$7.55M Sell
164,147
-128,758
-44% -$6.72M 0.05% 252
2016
Q2 		$14.7M Buy
292,905
+10,063
+4% +$536K 0.1% 192
2016
Q1 		$15.1M Sell
282,842
-648
-0.2% -$38K 0.1% 189
2015
Q4 		$18.6M Sell
283,490
-18,908
-6% -$1.17M 0.12% 167
2015
Q3 		$17.1M Sell
302,398
-12,832
-4% -$832K 0.12% 172
2015
Q2 		$18.6M Sell
315,230
-7,104
-2% -$438K 0.11% 163
2015
Q1 		$20.1M Buy
322,334
+8,698
+3% +$506K 0.13% 153
2014
Q4 		$18M Buy
313,636
+10,696
+4% +$596K 0.11% 158
2014
Q3 		$16.3M Buy
302,940
+285,137
+1,602% +$15.1M 0.1% 167
2014
Q2 		$933K Sell
17,803
-346
-2% -$17.7K 0.04% 307
2014
Q1 		$959K Sell
18,149
-8,117
-31% -$375K 0.04% 289
2013
Q4 		$1.05M Buy
26,266
+4,138
+19% +$163K 0.04% 265
2013
Q3 		$836K Buy
22,128
+768
+4% +$30K 0.04% 266
2013
Q2 		$837K Buy
+21,360
New +$832K 0.04% 276

Other funds holding TEVA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
HIIFS
Harel Insurance Investments & Financial Services Ramat Gan, Israel $20.6B AUM 59.59% 1-Year Est. Return
PF
Phoenix Financial Givatayim, Israel $14.6B AUM 57.48% 1-Year Est. Return
WCM Investment Management
WCM Investment Management Laguna Beach, California $55.2B AUM 57.07% 1-Year Est. Return
CI
Clal Insurance Tel-Aviv, Israel $22.3B AUM 79.91% 1-Year Est. Return
MMH
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $15.6B AUM 71.29% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
LIM
Lingotto Investment Management London, United Kingdom $4.67B AUM 70.24% 1-Year Est. Return

M&T Bank's TEVA Position: Q2 2026 in Review

M&T Bank increased its Teva Pharmaceuticals (TEVA) stake by 8.3% in Q2 2026, buying an estimated $273K and bringing the position to 106,646 shares worth $3.61M. The position accounts for 0.01% of the portfolio, ranked #485.

M&T Bank first reported a position in TEVA in Q2 2013 and has held it in 28 quarters since. The position peaked at $20.1M in Q1 2015. 673 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.

  • M&T Bank held 106,646 shares of Teva Pharmaceuticals worth $3.61M as of Q2 2026.
  • M&T Bank bought 8,183 Teva Pharmaceuticals shares in Q2 2026, an estimated $273K.
  • Teva Pharmaceuticals made up 0.01% of M&T Bank's portfolio in Q2 2026, its #485 holding.
  • M&T Bank first reported a position in Teva Pharmaceuticals in Q2 2013 and has held it in 28 quarters since.
  • M&T Bank's Teva Pharmaceuticals position peaked at $20.1M in Q1 2015.
  • 673 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.

Based on M&T Bank's 13F filing for Q2 2026, filed 4 Aug 2026.